Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beverly Moy

Showing results (101-110 of 168) with videos related to

Pageof 17
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 6, 2020
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US populationKassidy Beyerlin, Rachel Jimenez, Mark Zangardi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2021
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution StudySarah Asad, Carlos H Barcenas, Richard J Bleicher, et al.
Breast Cancer Research and Treatment|June 17, 2022
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysisTal Sella, Pedro Exman, Siyang Ren, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast CancerLaura Spring, Rachel Greenup, Andrzej Niemierko, et al.
Cancer|July 27, 2004
Mammographic screening: patterns of use and estimated impact on breast carcinoma survivalKaren Blanchard, James A Colbert, Dhruv Puri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experienceAntonio C Wolff, Amanda L Blackford, Kala Visvanathan, et al.
Breast (Edinburgh, Scotland)|January 21, 2023
Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort studyAdith Abraham, Carlos H Barcenas, Richard J Bleicher, et al.
Breast Cancer Research and Treatment|September 17, 2018
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancerLaura Spring, Andrzej Niemierko, Stephanie Haddad, et al.
The International Journal of Biological Markers|September 28, 2012
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapyRimoun R Boutrus, Rita F Abi Raad, Irene Kuter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline UpdateN Lynn Henry, Mark R Somerfield, Zoneddy Dayao, et al.
Pageof 17

Showing results (101-110 of 168) with videos related to

Sort By:
Pageof 17
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 6, 2020
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US populationKassidy Beyerlin, Rachel Jimenez, Mark Zangardi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2021
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution StudySarah Asad, Carlos H Barcenas, Richard J Bleicher, et al.
Breast Cancer Research and Treatment|June 17, 2022
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysisTal Sella, Pedro Exman, Siyang Ren, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast CancerLaura Spring, Rachel Greenup, Andrzej Niemierko, et al.
Cancer|July 27, 2004
Mammographic screening: patterns of use and estimated impact on breast carcinoma survivalKaren Blanchard, James A Colbert, Dhruv Puri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experienceAntonio C Wolff, Amanda L Blackford, Kala Visvanathan, et al.
Breast (Edinburgh, Scotland)|January 21, 2023
Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort studyAdith Abraham, Carlos H Barcenas, Richard J Bleicher, et al.
Breast Cancer Research and Treatment|September 17, 2018
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancerLaura Spring, Andrzej Niemierko, Stephanie Haddad, et al.
The International Journal of Biological Markers|September 28, 2012
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapyRimoun R Boutrus, Rita F Abi Raad, Irene Kuter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline UpdateN Lynn Henry, Mark R Somerfield, Zoneddy Dayao, et al.
Pageof 17